<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820573</url>
  </required_header>
  <id_info>
    <org_study_id>35464</org_study_id>
    <nct_id>NCT00820573</nct_id>
  </id_info>
  <brief_title>Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM</brief_title>
  <official_title>Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after
      6 weeks of treatment:

      Objective: To assess the effects of co-administration of sitagliptin and metformin compared
      to placebo on hepatic glucose production (HGP).

      Hypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin
      provides greater reduction in hepatic glucose production (HGP) compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY:

      In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after
      6 weeks of treatment:

      Objective: To assess the effects of co-administration of sitagliptin and metformin compared
      to placebo on hepatic glucose production (HGP).

      Hypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin
      provides greater reduction in hepatic glucose production (HGP) compared to placebo.

      SECONDARY:

      In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after
      6 weeks of treatment:

        1. Objective: To assess the effects of co-administration of sitagliptin and metformin
           compared to placebo on post-meal glucose during meal tolerance test (MTT).

           Hypothesis: After 6 weeks of treatment the co-administration of sitagliptin and
           metformin provides greater reduction in the total glucose AUC (0-6 hr) during MTT
           compared to placebo.

        2. Objective: To assess the effects of co-administration of sitagliptin and metformin
           compared to placebo on fasting plasma glucose (FPG).

           Hypothesis: After 6 weeks of treatment the co-administration of sitagliptin and
           metformin provides greater reduction in FPG compared to placebo.

        3. Objective: To assess the effects sitagliptin alone compared to placebo on HGP.
           Hypothesis: After 6 weeks of treatment, sitagliptin alone provides greater reduction in
           HGP compared to placebo

      EXPLORATORY OBJECTIVES:

      (i) Objective: after 6 weeks of treatment, to assess the effects co-administration of
      sitagliptin and metformin compared to placebo on:

        1. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and
           post-meal GIP).

        2. glucagon concentration (fasting and post-meal).

        3. parameters of insulin secretion and insulin sensitivity.

        4. splanchnic glucose uptake.

           (ii) Objective: after 6 weeks of treatment, to assess the effects co-administration of
           sitagliptin and metformin compared to treatment with sitagliptin alone and metformin
           alone on:

        5. glucose concentration (fasting and total glucose AUC [0-6 hr]).

        6. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and
           post-meal GIP).

        7. glucagon concentration (fasting and post-meal).

        8. parameters of insulin secretion and insulin sensitivity.

        9. HGP.

       10. splanchnic glucose uptake. (iii) Objective: after 6 weeks of treatment, to assess the
           effects of sitagliptin alone and metformin alone compared to placebo on:

       11. glucose concentration (fasting and total glucose AUC [0-6 hr]).

       12. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and
           post-meal GIP).

       13. glucagon concentration (fasting and post-meal).

       14. parameters of insulin secretion and insulin sensitivity.

       15. HGP.

       16. splanchnic glucose uptake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production (EGP).</measure>
    <time_frame>6 weeks</time_frame>
    <description>Baseline endogenous glucose production prior to a mixed meal tolerance test (placebo) and following 6 weeks of either sitagliptin, metformin or sitagliptin plus metformin combination therapy in all 16 participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).</measure>
    <time_frame>6 weeks</time_frame>
    <description>The degree of suppression of baseline endogenous glucose production was measured in absolute values and as a percent of basal values at the end of each 6-week therapeutic period. The absolute values obtained in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose 6 Weeks After Therapy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Basal pasma glucose was determined with the glucose oxidase method after each specific 6 week treatment. The absolute values obtained of basal plasma glucose at the end of each 6-week therapeutic period in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline</measure>
    <time_frame>360 min</time_frame>
    <description>The absolute values of mean plasma glucose post-meal (360 minutes)were determined after each specific 6 week treatment and these absolute values after each specific sequence therapy were compared amongst all groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be provided for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin to be provided for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin to be provided for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin+Metfromin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin + Metformin combined will be provided for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>tablet, 100 mg/day, 6 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>tablet, 1000 mg/ bid, 6 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin + Metformin</intervention_name>
    <description>tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks</description>
    <arm_group_label>Sitagliptin+Metfromin</arm_group_label>
    <other_name>Januvia and glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following inclusion criteria to participate in the
             study.

          -  Patients with screening values/findings outside ranges described in the protocol may
             have one repeat determination performed and if the repeat value satisfies the
             criterion, they may continue in the screening process.

          -  If the repeat value does not satisfy the criterion, the principal investigator will
             review the abnormal laboratory value and decide whether the subject may continue in
             the screening process.

          -  All screening laboratory measurements are to be performed after an overnight fast ≥10
             hours in duration.

          -  Patients must be able to communicate meaningfully with the investigator and must be
             legally competent to provide written informed consent.

          -  Patients can be either male or female.

          -  Patients are ≥18 and ≤70 years of age on the day of signing informed consent.

          -  Patients must meet the current American Diabetes Association criteria for the
             diagnosis of type 2 diabetes mellitus

          -  Patients must be on diet or diet plus exercise therapy.

          -  Patients must have a HbA1c ≥ 7.5% and ≤ 9.5%

          -  Patients must have a BMI of 23-40 kg/m2

          -  Patients must have the following laboratory values:

               -  Hematocrit Males ≥ 34 vol%

               -  Females ≥ 33vol%

               -  Serum creatinine ≤ 1.5 mg/dL in males and ≤ 1.4 mg/dL in females

               -  AST (SGOT): ≤ 2.5 times upper limit of normal

               -  ALT (SGPT): ≤ 2.5 times upper limit of normal

               -  Alkaline phosphatase ≤ 2.5 times upper limit of normal

               -  If serum creatinine is &gt; 1.5 mg/dl in males and &gt; 1.4 mg/dl in females, the
                  Principal Investigator can include the patient if the measured GFR is &gt;70 ml/min
                  (24 hour creatinine clearance)

          -  Patients must have been on a stable dose of allowed chronic medications for ≥30 days
             prior to entering the study.

          -  Only patients whose body weight has been stable (±4 pounds) over the three months
             prior to the study will be included.

        Exclusion Criteria:

          -  Patients are excluded from participation in the study if they meet any of the
             following criteria:

               -  Patient has type 1 diabetes.

               -  Patient has received insulin for more than one week within the previous year
                  prior to entry.

               -  Patient has been treated with exenatide or a non-TZD, oral antihyperglycemic
                  agent within the last 2 months or with a TZD (pioglitazone or rosiglitazone)
                  within the last 4 months.

               -  Patient is receiving any medications with known adverse effects on glucose
                  tolerance (e.g., systemic glucocorticoids, psychotropic drugs like clozapine,
                  olanzapine, haloperidol, risperidone). Note: Patients may be taking stable doses
                  of estrogens, other hormonal replacement therapy, or lipid and blood pressure
                  lowering agents if the patient has been on these agents for the prior three
                  months.

               -  Patient has evidence of a significant cardiovascular disorder within 6 months of
                  signing informed consent (e.g. acute coronary syndrome, coronary artery
                  intervention, stroke or transient ischemic neurological disorder) or has New York
                  Heart Association Classification greater than Class 2; or has significant
                  findings on ECG (other than non-specific ST-T wave changes); or peripheral
                  vascular disease (history of claudication); or has dyspnea on exertion of one
                  flight or less, or abnormal breath sounds on auscultation.

               -  Patient has a history of intolerance or hypersensitivity to a DPP-4 inhibitor or
                  to metformin.

               -  Patient is pregnant or plans to become pregnant within the projected duration of
                  the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenio Cersosimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of TX Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <results_first_submitted>November 5, 2012</results_first_submitted>
  <results_first_submitted_qc>December 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Eugenio Cersosimo</investigator_full_name>
    <investigator_title>Associate Professor Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Texas Diabetes Institute from March 2010 July 2011</recruitment_details>
      <pre_assignment_details>A 4 week washout period for those subjects on oral anti-diabetic therapy with sulfonylureas was used in 7 subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo,Sitagliptin,Metformin and Sitagliptin Plus Metformin</title>
          <description>Sequence as described, starting placebo therapy for 6 weeks,followed by sitagliptin 100 mg once daily, then metformin 1000 mg twice daily for 6 weeks and the combination sitagliptn plus metformin for the final 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin, Metformin, Sitagliptin Plus Metformin, Placebo</title>
          <description>Sequence as described, starting with sitagliptin 100 mg once daily, then metformin 1000 mg twice daily for 6 weeks, combination sitagliptn plus metformin for 6 weeks and then placebo therapy for the final 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Metformin, Sitagliptin Plus Metformin, Sitagliptin,Placebo</title>
          <description>Sequence as described, starting with metformin 1000 mg twice daily for 6 weeks, combination sitagliptn plus metformin for 6 weeks, then sitagliptin 100 mg daily followed by placebo therapy for the final 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin Plus Metformin, Sitagliptin, Placebo,Metformin</title>
          <description>Sequence as described, starting with combination sitagliptn plus metformin for 6 weeks, then sitagliptin 100 mg daily placebo therapy for 6 weeks and finally metforminfor 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>all subjects after 6 weeks of placebo therapy</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>all subjects after receiving 6 weeks of metformin therapy</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin</title>
          <description>all subjects after receiving 6 weeks of sitagliptin therapy</description>
        </group>
        <group group_id="B4">
          <title>Metformin Plus Sitagliptin</title>
          <description>all subjects after receiving 6 weeks of combined sitagliptin plus metformin therpay</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production (EGP).</title>
        <description>Baseline endogenous glucose production prior to a mixed meal tolerance test (placebo) and following 6 weeks of either sitagliptin, metformin or sitagliptin plus metformin combination therapy in all 16 participants</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin Plus Metformin</title>
            <description>All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order</description>
          </group>
        </group_list>
        <measure>
          <title>Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production (EGP).</title>
          <description>Baseline endogenous glucose production prior to a mixed meal tolerance test (placebo) and following 6 weeks of either sitagliptin, metformin or sitagliptin plus metformin combination therapy in all 16 participants</description>
          <units>mg/kg.min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.2"/>
                    <measurement group_id="O3" value="1.7" spread="0.2"/>
                    <measurement group_id="O4" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A general unstructured variance-covariance matrix (ANOVA) was applied for measurements at different periods. Between-group comparisons after 6 wks of treatment were assessed using the ANOVA model at alpha=0.05 (two-sided).
16 subjects provide ~90% power to detect difference in EGP of 0.28 mg/kg.min (95% CI = 0.17 mg/kg.min).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose 6 Weeks After Therapy</title>
        <description>Basal pasma glucose was determined with the glucose oxidase method after each specific 6 week treatment. The absolute values obtained of basal plasma glucose at the end of each 6-week therapeutic period in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
        <time_frame>6 weeks</time_frame>
        <population>All 16 participants were analyzed using ANOVA to compare results after each 6 week period of exposure to therapeutic agent(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin Plus Metformin</title>
            <description>All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose 6 Weeks After Therapy</title>
          <description>Basal pasma glucose was determined with the glucose oxidase method after each specific 6 week treatment. The absolute values obtained of basal plasma glucose at the end of each 6-week therapeutic period in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
          <population>All 16 participants were analyzed using ANOVA to compare results after each 6 week period of exposure to therapeutic agent(s)</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="4"/>
                    <measurement group_id="O2" value="145" spread="5"/>
                    <measurement group_id="O3" value="150" spread="4"/>
                    <measurement group_id="O4" value="120" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>multivariate analysis was performed to compare results amongst all four groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).</title>
        <description>The degree of suppression of baseline endogenous glucose production was measured in absolute values and as a percent of basal values at the end of each 6-week therapeutic period. The absolute values obtained in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
        <time_frame>6 weeks</time_frame>
        <population>power calculations with data from previous similar studies</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sitagliptin
Sitagliptin : tablet, 100 mg/day, 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin
Metformin : tablet, 1000 mg/ bid, 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin + Metformin
Sitagliptin and Metformin : tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin + Metformin</title>
            <description>placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).</title>
          <description>The degree of suppression of baseline endogenous glucose production was measured in absolute values and as a percent of basal values at the end of each 6-week therapeutic period. The absolute values obtained in each sequence study group (both basal and post-meal) were compared amongst all groups.</description>
          <population>power calculations with data from previous similar studies</population>
          <units>mg/kg.min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.2"/>
                    <measurement group_id="O2" value="1.6" spread="0.2"/>
                    <measurement group_id="O3" value="1.7" spread="0.2"/>
                    <measurement group_id="O4" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline</title>
        <description>The absolute values of mean plasma glucose post-meal (360 minutes)were determined after each specific 6 week treatment and these absolute values after each specific sequence therapy were compared amongst all groups.</description>
        <time_frame>360 min</time_frame>
        <population>power calculation based on previous data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sitagliptin
Sitagliptin : tablet, 100 mg/day, 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin
Metformin : tablet, 1000 mg/ bid, 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin + Metformin
Sitagliptin and Metformin : tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin+Metformin</title>
            <description>placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline</title>
          <description>The absolute values of mean plasma glucose post-meal (360 minutes)were determined after each specific 6 week treatment and these absolute values after each specific sequence therapy were compared amongst all groups.</description>
          <population>power calculation based on previous data</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="5"/>
                    <measurement group_id="O2" value="191" spread="4"/>
                    <measurement group_id="O3" value="195" spread="4"/>
                    <measurement group_id="O4" value="161" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>March 2010 to July 2011</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>all subjects after 6 weeks of placebo therapy</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>all subjects after receiving 6 weeks of metformin therapy</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin</title>
          <description>all subjects after receiving 6 weeks of sitagliptin therapy</description>
        </group>
        <group group_id="E4">
          <title>Metformin Plus Sitagliptin</title>
          <description>all subjects after receiving 6 weeks of combined sitagliptin plus metformin therpay</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenio Cersosimo, MD PhD</name_or_title>
      <organization>University of Texas HSC at San Antonio</organization>
      <phone>210 358 7200</phone>
      <email>Eugenio.cersosimo@uhs-sa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

